Orthocell’s US patent will cover the manufacture of CelGro®, a unique and customisable collagen medical device that can help in the repair of bone and neural defects.
Regenerative medicine company Orthocell Limited (ASX:OCC) announced today that it has secured a new US divisional patent for CelGro®.
CelGro® is a customisable collagen medical device manufactured using Orthocell’s SMRT™ tissue engineering process.
The product has demonstrated “high-quality outcomes” in bone and nerve tissue repair, the company claims.
The patents entitled “Method for Producing a Collagen Membrane and Use Thereof” establishes the intellectual property (IP) of the CelGro® platform for soft tissue regeneration and repair application in the U.S.
As of recent, Orthocell has secured 11 patent families for its regenerative medicine products. The Company has already received patents for CelGro® in Australia, Canada, China, Europe, Japan, New Zealand and Singapore.
Orthocell’s U.S. patents are valid until June 2033.
Commenting on the successful patent application, Orthocell Managing Director Paul Anderson said: “This is an important patent that further protects and strengthens our IP position for CelGro® providing greater layers of protection.
“This patent also complements the recent market approval of the first CelGro® product, Striate+ for dental bone and soft tissue repair procedures approved in the US, EU and Australia.”
Striate+ is a CelGro® flagship product and the first to gain US, EU and AUS approval.
The company claims that Striate+ has “distinct advantages” over similar products in the regenerative market.
“Orthocell is well-positioned to secure a distribution partner and establish Striate+ as the best-in-class dental resorbable collagen membrane.”